Pharmaceutisch Weekblad

, Volume 11, Issue 1, pp 23–26 | Cite as

A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients

Preliminary pharmacokinetic results
  • Anton J. M. Loonen
  • Peter J. M. M. Toll
  • Jan R. Nijdam
Short Communications


In an open, randomized, two-centre, cross-over study 20 patients formerly adjusted to a stable oral twice daily 200–600 mg carbamazepine dose, used ordinary tablets and divitabs (a new sustained-release formulation) for periods of three weeks, whereafter the serum level courses of carbamazepine and its metabolite carbamazepine-10,ll-epoxide were measured. The mean peak/mean trough carbamazepine-serum concentration ratio was slightly lower after the intake of divitabs in comparison to normal formulation: 1.14±0.447 versus 1.23±0.545 (mean ±SD). The mean trough levels of carbamazepine and its metabolite were 9% and 16% lower in the case of divitabs. In patients with peak/trough carbamazepine-serum level ratios of at least 1.30 after the intake of normal formulation, divitabs had a significant advantage.


Biopharmaceutics Carbamazepine Clinical trials Drug compounding Pharmacokinetics Tablets Tablets, controlled release 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schobben AFAM. Pharmacokinetics and therapeutics in epilepsy. Nijmegen: Catholic University of Nijmegen, 1979. Dissertation.Google Scholar
  2. 2.
    Sillanpää M. Carbamazepine. Pharmacology and clinical uses. Acta Neurol Scand 1981;64(suppl 88).Google Scholar
  3. 3.
    Dalessio DJ. Trigeminal neuralgia; a practical approach to treatment. Drugs 1982;24:248–55.PubMedGoogle Scholar
  4. 4.
    Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 1984;20:572–84.PubMedGoogle Scholar
  5. 5.
    Wilbur R., Kulik FA. Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants. Am J Hosp Pharm 1981;38:1138–43.PubMedGoogle Scholar
  6. 6.
    Evans RW, Gualtieri CT. Carbamazepine: a neuropsychological and psychiatric profile. Clin Neuropharmacol 1985;8:221–41.PubMedGoogle Scholar
  7. 7.
    Lerer B. Alternative therapies for bipolar disorder. J Clin Psychiatry 1985;46:309–16.PubMedGoogle Scholar
  8. 8.
    Schmidt S, Greil W. Carbamazepin in der Behandlung psychiatrischer Erkrankungen.Übersicht zum gegenwärtigen Stand der Forschung. Nervenarzt 1987;58:719–36.PubMedGoogle Scholar
  9. 9.
    Höppener RJ, Kuyer A, Meijer JWA,et al. Correlations between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21:341–50.PubMedGoogle Scholar
  10. 10.
    Tomson T. Interdosage fluctuations in plasma carbamazepine concentrations determine intermittent side effects. Arch Neurol 1984;41:830–4.PubMedGoogle Scholar
  11. 11.
    Aldenkamp AP, Alpherts WCJ, Moerland MC, Ottevanger N, Van Parys JAP. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987;28:507–14.PubMedGoogle Scholar
  12. 12.
    Nolen WA, Jansen GS, Broekman M. Measuring plasma levels of carbamazepine; a pharmacokinetic study in patients with affective disorders. Pharmacopsychiatria 1988;21:252–4.Google Scholar
  13. 13.
    Loonen AJM, Zwanikken GJ. Farmaca, Psychofarmaca, Klinisch onderzoek. Ontwikkeling, beproeving en toepassing van (psycho)farmaca. 's-Hertogenbosch: WULCO, 1987.Google Scholar
  14. 14.
    Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956.Google Scholar
  15. 15.
    Richens A. Interactions with antiepileptic drugs. Drugs 1977;13:266–75.PubMedGoogle Scholar
  16. 16.
    Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 1984;25(suppl 2):S118–31.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • Anton J. M. Loonen
    • 1
  • Peter J. M. M. Toll
    • 2
  • Jan R. Nijdam
    • 3
  1. 1.Psychiatrische Instituten van de GodshuizenGB VughtThe Netherlands
  2. 2.Centrale Apotheek GodshuizenNL 's-HertogenboschThe Netherlands
  3. 3.Psychiatrische Instituten van de GodshuizenVught

Personalised recommendations